Micropace Pty Ltd
Roman Greifeneder, MSc. has a diverse work experience spanning over several years. Roman'smost recent role is as the CEO & Regulatory at Micropace Pty Ltd, starting in August 2020. Prior to that, they held the position of COO, Executive Director & Regulatory at Khelix for over a decade, from July 2009 to August 2020. Roman also served as the VP at Ventracor from November 2003 to June 2009. Earlier in their career, they worked as a Manufacturing Engineering Manager/NPI Manager at ResMed from June 1998 to November 2003, and as a QA/NPI Engineer at Telectronics from June 1993 to November 1996.
Roman Greifeneder, MSc. obtained a Master's degree in Science from Universität für Weiterbildung Krems from 2019 to 2020. Prior to this, they pursued studies in Management at AGSM @ UNSW Business School from 2001 to 2003, achieving a Distinction Grade.
This person is not in any teams
This person is not in any offices
Micropace Pty Ltd
Micropace is a manufacturing company that designs and manufactures EP cardiac stimulators.The company's flagship product is the EPS320B Cardiac Stimulator which helps the rapid case flow in the EP lab environment through its simple intuitive graphical interface, intelligent use of automation, and pre-programmed protocols arising from yearsof experience in the EP Lab.The EPS320, in contrast to most hardware stimulators, may be operated by new or rotating staff after only minutes of training. The same product however caters for the power-user, providing leading edge advanced functions required for the latest in clinical and research applications such as AICD-style ATP testing, CRT / bi-ventricular pacing and HF autonomic stimulation in atrial fibrillation work.EPS320B sales have been growing at an average of 40% per annum and the product is currently supplied with two of the three major EP recording systems worldwide. Micropace stimulators have been installed in over 800 sites in USA since 2002 and over 1500 sites worldwide and sales growth is expected to continue by targeting the existing stimulator replacement market.